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Abstract
Emery–Dreifuss muscular dystrophy (EDMD) is a neuromuscular disease characterized by early contractures, slowly progressive muscular
weakness and life-threatening cardiac arrhythmia that can develop into cardiomyopathy. In X-linked EDMD (EDMD1), female carriers are usually
unaffected. Here we present a clinical description and in vitro characterization of a mildly affected EDMD1 female carrying the heterozygous EMD
mutation c.174_175delTT; p.Y59* that yields loss of protein. Muscle tissue sections and cultured patient myoblasts exhibited a mixed population
of emerin-positive and -negative cells; thus uneven X-inactivation was excluded as causative. Patient blood cells were predominantly emerin-
positive, but considerable nuclear lobulation was observed in non-granulocyte cells – a novel phenotype in EDMD. Both emerin-positive and
emerin-negative myoblasts exhibited spontaneous differentiation in tissue culture, though emerin-negative myoblasts were more proliferative than
emerin-positive cells. The preferential proliferation of emerin-negative myoblasts together with the high rate of spontaneous differentiation in both
populations suggests that loss of functional satellite cells might be one underlying mechanism for disease pathology. This could also account for
the slowly developing muscle phenotype.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).
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1. Introduction
Emery–Dreifuss muscular dystrophy (EDMD) is a
neuromuscular disease characterized by early contractures,
slowly progressive muscular weakness and life-threatening
cardiac arrhythmia that can develop into cardiomyopathy.
Contractures affecting the elbows, Achilles tendons and post-
cervical muscles usually occur as the first clinical manifestation
[1]. EDMD is genetically variable and thus far ~50% of patients
have been linked to EMD (STA), LMNA, FHL1, SYNE1, SYNE2,
LUMA and SUN1 mutations [2]. Over 90% of linked patients
have dominant mutations in LMNA [3] or recessive mutations in
the X-chromosomal EMD gene [4]. The EMD gene encodes
emerin, a 254 amino acid protein that is anchored in the nuclear
envelope with a transmembrane span close to its C-terminus
[5]. Most EMD mutations are predicted to cause loss of the
protein, but missense mutations have also been reported. Out of
97 EMD mutations reported on http://www.umd.be only 6
mutations (affecting 5 codons) are missense mutations. Various
reports have proposed that the disease results from defective
emerin function affecting gene expression, cell proliferation
and differentiation, or cellular susceptibility to mechanical
stress damage [6].
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Female carriers of EMD mutations are usually
asymptomatic; however, cardiac involvement has been
occasionally though rarely described [7]. In all thus far reported
cases of symptomatic females the clinical manifestation has
been associated with unequal X-inactivation. However, it is also
possible that the phenotype in symptomatic carriers could be
caused by modifying mutations similar to how modifying
mutations have been previously shown to affect disease
severity. For example, combinations of EMD and LMNA
mutations [8] as well as EMD and DES (the gene encoding the
muscle intermediate filament desmin) [9] can increase the
severity of EDMD. Findings in tissue culture indicate that
mutations in SUN1, SUN2 and SYNE1 also act as severity
modifiers in muscular disease [10,11]. The remarkable intra-
and inter-familial variability regarding onset and severity of
EDMD [12–16] makes it likely that severity modifiers are
frequently involved, possibly even involving mutations that on
their own do not cause a noticeable phenotype.
Here we report a symptomatic female carrying an emerin
mutation that has also been found in her affected father. We
have excluded uneven X-inactivation as a causative factor,
finding that the majority of muscle as well as blood cells
express the emerin wild-type allele. This makes a modifying
mutation likely and raises the question of the contribution
of each mutation to the disease. Nonetheless, analysis of the
growth and differentiation potential of emerin-positive and
emerin-negative cells in the population suggests a model
whereby the emerin mutation contributes to depletion of a
functional satellite cell population. Finally, as the X-linked
EMD gene would not normally have been sequenced for a
female presenting with EDMD this study highlights the
importance of extensive analysis of the pedigree when
searching for disease-causing mutations.
2. Materials and methods
2.1. Patient and controls
The patient attended the clinic followed by routine
diagnostic mutational analysis of the EMD (MIM *300384) and
LMNA (MIM *150330) genes. All materials (blood and muscle
biopsies to generate myoblast lines) included in this study were
taken with informed consent of the donors and with approval of
the local ethics board.
2.2. Mutational analysis and tissue culture
Sanger sequencing was used to sequence the coding areas
and exon/intron boundaries of the LMNA and EMD genes.
Myoblasts were gained from a biopsy of biceps brachii muscle
performed in the index patient at age 16. These myoblasts
as well as myoblasts from an age matched control were grown
in tissue culture using skeletal muscle cell growth medium
(PromoCell, Heidelberg, Germany). Cells were kept from
reaching confluency to avoid differentiation. For differentiation
DMEM (containing 0.1% FBS, 5 mg/ml insulin and 5 mg/ml
transferin) was used. Cells were grown at 37 °C in a 5% CO2
incubator.
2.3. Analysis of leucocyte populations by flow cytometry
A typically principally mononuclear leucocyte fraction was
isolated from heparinized blood using Histopaque®-1077
(Sigma-Aldrich®) following the provided protocol. To
determine composition of the fraction, cells were analysed by
flow cytometry using fluorescently labelled antibodies to CD19
(Becton Dickinson, 555413) for B-cells, CD3 (Beckman
Coulter, A07746) for T-cells, CD66b (BioLegend, 305102) for
granulocytes, and CD14 (Becton Dickinson, 560349) for
macrophages and myeloid cells. After staining, cells were
analysed on an LSR II flow cytometer (BD Bioscience, UK)
equipped with 488 nm and 350 nm lasers and appropriate
filters. Cell debris and cell aggregates were excluded from
analysis by application of electronic gates and numbers of the
live singlet cells in each gate calculated using FlowJo software
(TreeStar, Inc).
2.4. Immunohistochemistry
Myoblasts were fixed with methanol (−20 °C). As a marker
for proliferation Ki-67 (Thermo Scientific, RM-9106-S0),
antibody was used [17]. Relocalization from the centrosome
to the nuclear envelope of PCM1 has been found to be an
early and reliable marker of differentiation [18] and so was
used to assess myoblast differentiation. For emerin
immunofluorescence staining of myoblasts and biopsy sections
MANEM1 antibody was used which recognizes emerin amino
acids 89–96 (GYNDDYYE) [19]. For stainings with leucocyte
type-specific antibodies the same fluorescently conjugated
antibody set that was used for flow cytometry was employed;
however, because the laser lines of the flow cytometer did not
match the filter sets of the microscope, secondary antibodies
were also used. All secondary antibodies were Alexafluor
conjugated and generated in donkey with minimal species
cross-reactivity. DNA was visualized with DAPI (4,6-
diamidino-2 phenylindole, dihydrochloride). To determine if
the small fragment encoded by the mutant allele is stably
expressed, Western blot analysis optimized for small MW
proteins was performed using Millipore Immobilon® PSQ
Transfer Membranes and following the manufacturer’s
instructions. The blot was probed with monoclonal antibody
MANEM14 against emerin amino acids 7–14 (LSDTELTT)
[19].
2.5. Microscopy and image analysis
Most images were obtained using a Nikon TE-2000
microscope equipped with a 1.45 NA 100× objective or a 20×
objective and CoolSnapHQ High Speed Monochrome CCD
camera (Photometrics, Marlow, UK). Image analysis was
performed using ImageJ software.
2.6. RNA depletion of emerin in control myoblasts
The previously published siRNA against emerin
5′GGUGGAUGAUGACGAUCUUtt-3′ [20] was transfected
into myoblasts using jetPRIME® (Polyplus) following the
manufacturer’s instructions.
128 P. Meinke et al. /Neuromuscular Disorders 25 (2015) 127–136
3. Clinical report
The 25-year-old female index patient of this family (IV-1,
Figs. 1 and 2A) had normal developmental milestones and
did not complain of muscle weakness during childhood.
Symptoms at onset, at the age of 12 years, were Achilles tendon
contractures along with myalgia of proximal muscles, mainly
after exercise. Since age 15 she complained about mild
proximal weakness during longer walks or when climbing
stairs. At examination at age 16, there was a mild proximal
weakness of 4–5/5, predominantly in the dorsal leg muscles,
mild scapular winging, mild scoliosis, no facial weakness, no
muscle atrophy, mild calf hypertrophy. Walking on tiptoes was
possible; walking on heels was moderately impaired due to
Achilles tendon contractures. At age 23, 4/5 weakness of small
hand muscles occurred. Creatine kinase levels were mildly
elevated with 180 U/l (normal <145). Electromyography was
repeatedly performed and showed a mild myopathic pattern in
proximal leg muscles. Motor and sensory nerve conduction
velocity was found normal. Starting at age 21, the patient
complained of palpitations and extrasystoles of the heart. At
age 23, ECG showed sinusarrhythmia, vertical heart, unspecific
ST elevations of maximal 0.1 mV in II, III, aVF, V5 and V6.
The 24 h ECG showed sinus rhythm, heart rate 74 (range
50–166), no relevant asystolia, 90 VES, 2523 SVES and no
high-grade dysrhythmia. Cardiac ultrasound, nocturnal pulse
oxymetry and lung function were found normal. Whole body
muscle MRI at age 23 showed mild asymmetric atrophy of the
shoulder girdle muscles, but no fatty replacement of muscle
tissue (Fig. 2B).
The father of the index patient (Fig. 1, III-2) was reported to
suffer from muscular dystrophy, but had not been genetically
characterized before. His symptoms started at age 4 with
Achilles tendon contractures, during disease progression
proximal weakness and atrophy occurred along with cardiac
arrhythmia requiring pacemaker implantation at age 25. The
father’s affected brother (Fig. 1, III-4) died from cardiac arrest
at age 35; he did not have a pacemaker. However, onset of
symptoms in three affected uncles to the father of the index
patient (Fig. 1, II-5, -6 and -7) was reported to have started not
before age 20. Since family history had revealed only male
affection through three generations, EDMD1 was suspected.
The father of the index patient has nine further children (5
females, 4 males, age between eight and 20 years) with his
second wife, who were unfortunately not available for
examination. However, one of the five daughters (Fig. 1, IV-5)
is reported to have Achilles tendon contractures. The other
daughters have so far not shown any symptoms, but none of
them was genetically or clinically tested and most are still
younger than the index patient at the time of first clinical
manifestation.
Fig. 1. Pedigree of the patient. Arrow indicates the index patient.
Fig. 2. EDMD pathologies in the patient. A) The index patient shows a mild
limb girdle phenotype with calf hypertrophy, Achilles tendon contractures and
mild scapular winging. B) Whole body muscle MRI shows mild asymmetric
atrophy of the shoulder girdle muscles, prominent calf muscles, but no fatty
replacement of muscle tissue.
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4. Results and discussion
Looking only at the last two generations of the family,
inheritance of the disease appeared to be dominant, yet except
for the index patient the extended inheritance matches that for
an X-linked gene. Sequencing the index patient (Fig. 1, IV-1)
for changes in the LMNA and EMD genes identified no LMNA
mutation, but did identify the heterozygous EMD mutation
c.174_175delTT (p.Y59*). The same mutation was found to be
hemizygous in the affected father (Fig. 1, III-2). This mutation
has not been reported before, but another mutation causing an
early stop codon at the same position (c.177T > A; p.Y59*) has
been found in an affected male suffering EDMD1 [21]. Other
EMD mutations resulting in an early stop codon are known to
cause EDMD1 in hemizygous patients and, in fact, emerin
insufficiency accounts for the majority of EDMD1 (http://
www.umd.be [22]). Therefore, the EMD p.Y59* mutation is
most likely causing disease in the father and uncle through loss
of emerin. However, according to this mechanism, the
heterozygous patient should not be affected. In emerinopathies,
a wide clinical intrafamilial and interfamilial variability is
reported, independent of the type or localization of the mutation
[23]. Varying heart block or cardiomyopathy can occur in
otherwise healthy female EDMD1 carriers [1,22,24], but
muscle weakness and contractures due to EMD mutations have
hitherto not been described in females except in one female
carrier, heterozygous for an EMD mutation, where uneven
X-inactivation favouring the mutant allele was shown to be the
cause of the clinical manifestation [22].
A biopsy of biceps brachii muscle was performed on the
index patient, showing single rounded fibres but no fibrosis or
fatty degeneration, consistent with general appearance on MRI
(Fig. 2B). Immunohistochemical staining of the biopsy material
for emerin and lamin A showed that 87% of the cells were
positive for emerin using an antibody that would not recognize
the mutant fragment if expressed (Fig. 3A,B). Additional
staining of patient mononuclear blood cells showed an even
higher percentage of emerin-positive cells (>99% positive for
emerin, Fig. 3C). Also the majority of myoblasts gained from
this biopsy were expressing emerin (Fig. 3D). This excludes
loss of emerin through unequal X-inactivation favouring the
mutant allele as had been found for the other symptomatic
X-linked female.
A possible explanation could be that the pathology is
achieved in the presence of the wild-type allele if the predicted
truncated protein, too short to be functional in the male family
members that completely lack the wild-type protein, is
expressed and functions as a dominant-negative in the index
patient. The expression of the truncated protein (amino acids
1–59) was tested for by Western blot using an antibody to
emerin amino acids 7–14 and conditions for detection of small
peptides. This revealed no evidence of a possible truncated
protein (Fig. 3E).
Yet another possibility that cannot be excluded is a second
mutation modifying the disease. Modifying effects in EDMD1
have been shown for additional mutations in desmin or lamin A
[8,9]. As the onset of the disease in the father occurred earlier
than in his affected uncles, and apart from the index patient
another of his daughters seems to be affected too, a modifying
mutation seems likely. Additionally, the grandmother of the
index patient (Fig. 1; II-2), who, based on the pedigree, is an
obvious carrier of the disease allele, is reported as unaffected,
thus excluding a dominant effect of the emerin mutation.
The mixed population of emerin-positive and -negative
myoblasts from the muscle biopsy provided a good model to
investigate the effect of emerin loss in cells with identical
genetic background. During passaging of the myoblasts the
percentage of cells positive for emerin at first slightly increased
from passage 2 (~74%) until passage 4 (~80%), but then
steadily decreased until passage 10 (~38%). Inexplicably, the
emerin-positive population increased again in passage 11 to
49%, but the cells ceased to proliferate at that point and may
have entered senescence (Fig. 4A). Staining for the
proliferation marker Ki-67 [17] showed a higher proliferation
rate of emerin-negative cells compared to emerin-positive cells
starting from passage four (Fig. 4A,B). Depletion of emerin by
siRNA in control myoblasts similarly increased the cell
proliferation rate compared to cells transfected with control
siRNA (Fig. 4C). Emerin mutation or loss has been found to
affect cell cycle regulation [25,26] and COS-7 cells transfected
with an emerin EDMD mutation had increased cell-cycle length
[27]. Correspondingly, emerin null fibroblasts have a rapid
growth phenotype [28]. Also emerin-negative cells have
previously been reported to become dominant in culturing of
skin fibroblasts from a carrier of another EDMD emerin
mutation [29]. Here we have shown this effect for the first time
in muscle. Our data show that the emerin-negative cells had an
advantage in proliferation beginning at passage four. The fact
that this advantage was not observed until passage four might
reflect acclimation after freezing or the number of divisions
from a more complete satellite cell state. This could explain
how over time the emerin-negative cells became predominant in
the cultures.
Intriguingly, a high incidence of cells expressing
morphological characteristics of differentiated myotubes was
observed specifically in the patient myoblasts, even though cells
were always maintained subconfluent in culture and with high
serum medium. To investigate this phenomenon further, patient
and control myoblast differentiation was assessed in addition to
emerin status in exponentially growing cultures using PCM1
relocalization to the nuclear envelope as a marker of
differentiating cells [18]. PCM1 has an advantage over markers
that only appear upon differentiation because for these the level
of intensity can confuse results for cells in early stages of
differentiation whereas by being detectable at the centrosome in
undifferentiated myoblasts this is not a problem with PCM1.
This revealed a significantly higher differentiation rate of
patient myoblasts compared to the control (Fig. 4D,E). The
proportion of cells undergoing spontaneous differentiation in
the population of emerin-positive cells matched that in emerin-
negative cells through the first five passages; after that the
majority of the cells undergoing spontaneous differentiation
were emerin-positive (Fig. 4F). When differentiation was
actively induced by moving cells to skeletal muscle
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Fig. 3. Emerin staining excludes uneven X-inactivation. A–D) Patient cells were stained using an emerin antibody that would not recognize the predicted short
mutant version if expressed. A) Patient biopsy staining of biceps brachii muscle, arrows indicate emerin-negative nuclei. A higher magnification view of the boxed
section of the merged image is shown below it. B) Percentage of emerin positive cells (at least 200 nuclei counted for every bar). *cells ceased to proliferate at passage
11. C) Immunofluorescence staining of emerin in patient mononuclear blood cells indicates that nearly all cells are emerin positive. D) Cultured patient myoblasts
at passage 2. Arrows indicate emerin-negative nuclei. E) To determine if the predicted short mutant version of emerin was expressed in the patient cells an antibody
to an N-terminal peptide overlapping with the truncated sequence was used. A Western blot of patient and control myoblasts indicates the presence of only full length
emerin (MW 34 kDa).
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Fig. 4. Patient myoblasts preferentially undergo spontaneous differentiation in tissue culture. A) Percentage of patient emerin-positive and -negative cells expressing
the proliferation marker Ki-67 (at least 200 nuclei counted for each bar). B) Example for Ki-67 staining in patient myoblasts. C) Percentage of Ki-67 positive cells in
control myoblasts transfected with emerin siRNA or a scramble sequence control siRNA (at least 200 nuclei counted for each bar). D) Percentage of cells showing
spontaneous differentiation in patient cells and an age matched control myoblast cell line (at least 200 nuclei counted for every passage). E) Example for PCM1 staining
in patient myoblasts. F) Percentage of patient emerin-positive cells (at least 200 nuclei counted for each passage) and percentage of emerin-positive cells undergoing
spontaneous differentiation (50 single nuclei outside myotubes counted for p2–7, 20 for 8 + 9 and 3 for p10). G) Percentage of patient emerin-positive cells (at least
200 nuclei counted for each passage) and percentage of emerin-positive cells undergoing differentiation (50 single nuclei outside myotubes counted for all passages).
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differentiation medium for five days, a similar trend was
observed: emerin-positive as well as emerin-negative cells were
able to differentiate, but from passage six onwards there was a
clear advantage of emerin-positive cells to differentiate both
with and without induction (Fig. 4G). Moreover, all nuclei
inside myotubes were positive for emerin.
Both the proliferation and spontaneous differentiation
defects we observe in this female EDMD1 patient are
consistent with various observations of cell cycle and myogenic
effects in model systems. A mouse model lacking emerin
showed no overt muscle phenotype although muscle
regeneration seemed to be affected [30]. This lack of phenotype
Fig. 5. Blood cell distributions and nuclear lobulation in the patient. A) Dapi staining of nuclei from cells isolated from patient blood, 20× magnification. B) Dapi
staining of nuclei from cells isolated from patient blood, 100× magnification. C) FACS staining of cells isolated from patient and control blood for following markers:
CD3 (T-cells), CD14 (macrophages), CD66b (granulocytes) and CD19 (B-cells).
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is thought to be the result of a higher expression level of the
lamina-associated polypeptide1 (LAP1) in mouse cells
compared to human myoblasts [31]. Despite this, muscle tissue
from the emerin null mice showed abnormal cell-cycle
parameters and delayed myogenic differentiation with many
genes involved in MyoD and pRb pathways aberrantly
expressed [30]. A role of emerin in normal myogenesis has also
been shown where it inhibits binding of the transcription factor
Lmo7 to the MyoD promoter in C2C12 mouse myoblasts [32].
Additionally, cell cycle defects have been reported for
particular EDMD1 mutations when expressed in cultured cells
[27]. The faster proliferation of the emerin-negative patient
myoblasts and deficiencies in differentiation at later passages is
consistent with the mouse data; however, the observation of
spontaneous differentiation at early passages in both emerin-
positive and emerin-negative myoblasts suggests an additional
factor, such as an unknown modifying mutation, must
contribute to this second characteristic we observe in the patient
cells.
To our knowledge no blood phenotypes or pathology has
been previously reported for EDMD patients; however, in
analysing the patient blood to also test for uneven
X-inactivation, it was observed that a large number of cells had
highly lobulated nuclei (Fig. 5A,B). This would typically
indicate amplification of neutrophils, but the patient did not
show signs of any infection at the time the blood was taken.
Moreover, isolation of white blood cells was performed roughly
1 week after the blood was taken and neutrophils would not be
expected to survive that long, even when maintained in the cold.
Thus, the cells were analysed by flow cytometry to determine
and quantify the leucocyte cell types present in the population.
This analysis showed an unexpectedly large percentage of cells
Fig. 6. Highly lobulated nuclei in patient blood include non-granulocyte cells. A) Immunofluorescence staining of control blood cells for the following markers: CD3
(T-cells), CD14 (macrophages), CD66b (granulocytes). B) Immunofluorescence staining of patient blood cells for the same markers. The right panels are
magnifications of the boxed areas in the merged images.
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staining positive with the granulocyte marker CD66b (Fig. 5C).
In all 27% of the cells analysed in the patient sample were
positive for CD66b compared to only 1% of cells in a control
donor. The patient exhibited a corresponding loss of cells in
other populations, principally the CD3 positive cells which
dropped from 53% in the control donor to 8% in the patient.
Granulocytes, particularly neutrophils, are the only white blood
cell population defined by extensive nuclear lobulation. To
determine if the lobulated cells were all CD66b (granulocyte)
positive, immunofluorescence staining was performed using the
same leucocyte type-specific antibody set. Surprisingly, this
revealed that lobulated patient nuclei stained positive for
several different markers, including CD3 that should recognize
principally T-cells and CD14 that should recognize principally
macrophages, so that many highly lobulated cells were not
granulocytes (Fig. 6A,B). As most of the lobulated cells were
also positive for emerin using the antibody that would only
recognize the wild-type allele, this effect is likely the result of
the unknown modifying mutation we predict from the other
data. Modifying mutations identified previously in EDMD
patients have included both other nuclear envelope proteins and
non-nuclear envelope proteins. We postulate that this modifier
must be another nuclear envelope protein to have such a striking
effect on nuclear morphology in white blood cells.
5. Conclusions
This case study underscores the importance of extended
family history in choosing which genes to sequence first in
EDMD and potentially other genetically heterogeneous
diseases caused by both autosomal and X-linked genes. By
focusing on dominant inherited disease alleles the emerin
mutation could have easily been missed in this patient.
Most likely a second mutation is necessary to cause the full
phenotype observed in the female patient, but, if the findings in
culture reflect the situation in the patient tissue, the emerin
mutation plays the leading role. We postulate that the growth
advantage of the emerin-negative cells enables them to eventually
dominate the muscle cell population while emerin-positive
satellite cells are further depleted because of their tendency to
undergo spontaneous differentiation, likely due to the second
mutation. Thus, in the course of muscle use and ageing the two
mutations work together to deplete emerin-positive cells from the
population of muscle satellite cells, resulting in the later onset
dystrophic phenotype. However, tissue differences must also
affect the way the mutations work together because, in the blood,
the near absence of emerin-negative cells suggests a significant
survival disadvantage from the emerin mutation. This is the first
finding of blood cell effects in a case of EDMD. While difficulties
in accessing samples from other family members hinder
identification of the second mutation, the considerable nuclear
lobulation in non-granulocyte cells together with the aberrant cell
distributions suggests that the second mutation is also a nuclear
envelope protein. At the same time, as the father did not exhibit
unusually severe symptoms and the mother was completely
unaffected this second mutation is unlikely to be in one of the
existing genes linked to EDMD.
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